Mohammed Elmourtada Abdulgayoom: Exploring Hyperbaric Oxygen Therapy in Sickle Cell Disease
Mohammed Elmourtada Abdulgayoom, Clinical Hematology Specialist at Hamad Medical Corporation, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Hemoglobin, adding։
“I am pleased to share our newly published narrative review in Hemoglobin: Hyperbaric Oxygen Therapy in Sickle Cell Disease: A Narrative Review of Mechanisms, Clinical Applications, and Future Directions.
In this review, we explored the biological rationale and current clinical evidence for hyperbaric oxygen therapy (HBOT) as a potential adjunctive approach in selected complications of sickle cell disease, including vaso-occlusive pain, avascular necrosis, chronic leg ulcers, ophthalmic ischemia, and priapism.
While HBOT may improve tissue oxygenation and potentially reduce ischemia–reperfusion injury, the available evidence remains limited to case reports, small series, and early-phase studies.
Therefore, its role should currently be viewed as investigational and complementary to standard multidisciplinary care, rather than a routine treatment.
Further prospective and controlled studies are needed to define the patients most likely to benefit, optimal treatment protocols, and safety considerations in sickle cell disease.
Grateful to my co-authors for their valuable contributions: Awni Alshurafa, Jamil R Wafi, Tarek Abouzeid, Jaffer Altooq, and Mohamed A. Yassin.”
Title: Hyperbaric Oxygen Therapy in Sickle Cell Disease: A Narrative Review of Mechanisms, Clinical Applications, and Future Directions
Authors: Awni Alshurafa, Mohammed Abdulgayoom, Jamil R Wafi, Tarek Abouzeid, Jaffer Altooq,Mohamed A. Yassin
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 25, 2026, 04:44Tareq Abadl: Not Every Rh-Positive or Rh-Negative Result is That Simple
-
Apr 25, 2026, 04:44Michael Makris: Data Security and Research Integrity in Population Biobanks
-
Apr 25, 2026, 04:43Muriel De Vos: Real-World Outcomes in Haemophilia A Without Inhibitors in the United States
-
Apr 25, 2026, 04:43Abdullah Alswied: The Role of Intra-Apheresis in Stem Cell Collection
-
Apr 25, 2026, 04:10Nour Al-Mozain: Highlights on Therapeutic Plateletpheresis in Thrombocytosis
-
Apr 25, 2026, 03:502026 Applications Open for The International Outreach Initiative – ASH
-
Apr 25, 2026, 02:51Roche Extends Support to Expand Global Access to Hemophilia Care – WFH
-
Apr 25, 2026, 02:44WFH Congress 2026 Participation Overview – WFH
-
Apr 25, 2026, 02:33Sara Zalghout: Platelet Glycans as Diagnostic and Therapeutic Targets